search button

New bioactive peptide reduces the toxicity of chemotherapy drugs and increases drug sensitivity

  • Authors:
    • Xian Li
    • Huijun Wu
    • Xiaohui Ouyang
    • Bo Zhang
    • Xiulan Su

  • View Affiliations

  • Published online on: May 26, 2017     https://doi.org/10.3892/or.2017.5674
  • Pages: 129-140
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Anticancer bioactive peptide (ACBP) is extracted from normal goat spleens and exhibits antitumor activity alone and in combination with low cisplatin doses to achieve antitumor efficacy similar to higher cisplatin doses via sustained medication modes. In the present study, we investigated whether elevated levels of induced or normal ACBP in MKN‑45 gastric cancer (GC) cells may reduce their toxicity to oxaliplatin (L‑OHP) in a dose‑dependent manner. The growth inhibition rate (IR), morphological changes and gene expression were examined in MKN‑45 GC cells. Compared with normal ACBP, induced ACBP alone significantly enhanced the anticancer activity of L‑OHP‑mediated apoptosis and reduced the amount and side‑effects of L‑OHP (P<0.05). The inhibition of cancer cell growth at high concentrations of induced ACBP and L‑OHP was significantly more effective than at low concentrations. In addition, for the first time, we examined the potential of a combination of induced ACBP and L‑OHP to increase L‑OHP sensitivity in human gastric carcinoma xenograft tumors. Nude mice were implanted with human gastric carcinoma MKN‑45 cells and treated with an intraperitoneal injection of 0.5 ml of normal saline, 30 µg/ml ACBP, 20 µg/ml L‑OHP or 30 µg/ml ACBP + 20 µg/ml L‑OHP [combination of anticancer bioactive peptide and oxaliplatin (A+L)] via the tail vein twice a week. In vivo short‑term intermittent use of induced ACBP alone significantly inhibited MKN‑45 tumor growth. The combination of induced ACBP and L‑OHP also significantly improved the quality of life of the nude mice and reduced the toxicity of L‑OHP. Based on flow cytometry and gene expression analyses, A+L significantly increased the proportion of cells in the G2/M phase (P<0.05) relative to ACBP or L‑OHP alone, and short‑term intraperitoneal injection of ACBP increased the sensitizing effect of L‑OHP. Collectively, these results suggest that high levels of induced ACBP in combination with L‑OHP via a short‑term intermittent medication mode could be a useful clinical therapeutic strategy for GC.
View Figures
View References

Related Articles

Journal Cover

July-2017
Volume 38 Issue 1

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

  • Journal Metrics
  • Impact Factor: 4.2
  • Ranked Oncology
    (total number of cites)
  • CiteScore: 8.4
  • CiteScore Rank: Q1: #68/366 Oncology
  • Source Normalized Impact per Paper (SNIP): 0.786
  • SCImago Journal Rank (SJR): 0.812
International Symposium on Molecular Medicine Conference Banner
The Cancer Story
World Congress on Advances in Oncology and International Symposium on Molecular Medicine Conference Banner
World Academy Of Sciences Banner
Heyday Road Banner

0

Copy and paste a formatted citation
x
Spandidos Publications style
Li X, Wu H, Ouyang X, Zhang B and Su X: New bioactive peptide reduces the toxicity of chemotherapy drugs and increases drug sensitivity. Oncol Rep 38: 129-140, 2017
APA
Li, X., Wu, H., Ouyang, X., Zhang, B., & Su, X. (2017). New bioactive peptide reduces the toxicity of chemotherapy drugs and increases drug sensitivity. Oncology Reports, 38, 129-140. https://doi.org/10.3892/or.2017.5674
MLA
Li, X., Wu, H., Ouyang, X., Zhang, B., Su, X."New bioactive peptide reduces the toxicity of chemotherapy drugs and increases drug sensitivity". Oncology Reports 38.1 (2017): 129-140.
Chicago
Li, X., Wu, H., Ouyang, X., Zhang, B., Su, X."New bioactive peptide reduces the toxicity of chemotherapy drugs and increases drug sensitivity". Oncology Reports 38, no. 1 (2017): 129-140. https://doi.org/10.3892/or.2017.5674